These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21135271)

  • 1. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.
    Seruga B; Sterling L; Wang L; Tannock IF
    J Clin Oncol; 2011 Jan; 29(2):174-85. PubMed ID: 21135271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
    J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
    Anderson SJ
    J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring anticancer drugs.
    Prescrire Int; 2004 Jun; 13(71):104. PubMed ID: 15233149
    [No Abstract]   [Full Text] [Related]  

  • 7. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 9. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 12. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xyrem (sodium oxybate) postmarketing adverse event reporting system.
    Wang YG
    Sleep Med; 2010 Jun; 11(6):595; author reply 595-6. PubMed ID: 20362501
    [No Abstract]   [Full Text] [Related]  

  • 14. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 15. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA
    Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 20. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.